Intelligence Platform

Patents

Browse 416 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 10675358

Antibody adjuvant conjugates

Bolt Biotherapeutics, Inc. · Granted Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10676530

Methods for treating allergy and enhancing allergen-specific immunotherapy by administerin

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10676537

Antibody targeted to tissue factor, preparation method therefor, and use thereof

SHANGHAI MIRACOGEN INC. · Granted Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10662244

Methods for tumor treatment using CD3XCD20 bispecific antibody

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 26 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10633451

Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine

Ludwig-Maximilians-Universitat Munchen · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10626173

Method for treating pathological angiogenesis by administering an antibody that inhibits A

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10618967

Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. · Granted Tue Apr 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10620204

Antibody-mediated neutralization of Ebola viruses

The Board of Regents of the University of Texas System · Granted Tue Apr 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10596270

Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor ant

Sutro Biopharma, Inc. · Granted Tue Mar 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10570185

Method to detect autoantibody reactivity for deamidated insulin autoantigen in diabetes

Northwestern University · Granted Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10562975

CD6 antibody for treatment of T-cell mediated diseases or disorders

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10550193

Methods and antibody compositions for tumor treatment

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10548987

Antibody-drug conjugates for targeting CD56-positive tumors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10544223

Combination therapy with an anti-axl antibody-drug conjugate

ADC THERAPEUTICS SA · Granted Tue Jan 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10544232

Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10538590

Photosensitizing antibody-fluorophore conjugates

The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10532096

Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10519224

Treating headache comprising administering an antibody to calcitonin gene-related peptide

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10519240

Anti-FGFR1c antibody-FGF21 fusion proteins

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10501528

Immunoglobulin single variable domain antibody against RSV prefusion F protein

The United States of America, as represented by the Secretary, Health and Human Services · Granted Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10493149

Stable anti-OSMR antibody formulation

Kiniksa Pharmaceuticals, GmbH · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10479825

Antibody-mediated neutralization of Marburg virus

The Board of Regents of the University of Texas System · Granted Tue Nov 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10457726

Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumo

UNIVERSITY OF CONNECTICUT · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10450371

Monoclonal antibody and antigens for diagnosing and treating lung disease and injury

United States Government as represented by the Department of Veterans Affairs · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted